MabVax Therapeutics Holdings is a clinical-stage biopharmaceutical company. Co. discovers and develops proprietary human monoclonal antibody products for the diagnosis and treatment of a variety of cancers. Therapeutic vaccines under development were discovered at Memorial Sloan Kettering Cancer Center and are licensed to Co.'s subsidiary, MabVax Therapeutics, Inc. Co.'s development program is centered around its HuMab-5B1 antibody, which is discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial. The antigen the antibody targets is expressed on pancreatic cancers, small cell lung cancer, stomach, colon and other cancers. The MBVX average annual return 10 years is shown above.
The Average Annual Return on the MBVX average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MBVX average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MBVX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Video: Don't Forget Dividends in Average Annual Return!
